Using tumour pathology to identify people at high genetic risk of breast and colorectal cancers

Pathology

Volumn 44, Issue 2, 2012, Pages 89-98

  Hopper, J L ^a   Jenkins, M A ^a   Dowty, J G ^a   Dite, G S ^a   Apicella, C ^a   Keogh, L ^a   Win, A K ^a   Young, J P ^e   Buchanan, D ^e   Walsh, M D ^e   Rosty, C ^e,f   Baglietto, L ^b   Severi, G ^b   Phillips, K A ^a,c   Wong, E M ^c   Dobrovic, A ^a,c,d   Waring, P ^a   Winship, I ^a,c,d   Ramus, S J ^g   Giles, G G ^b   Southey, M C ^c   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CANCER EPIDEMIOLOGY CENTRE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

BRCA1; BRCA2; Breast cancer; Colorectal cancer; DNA mismatch repair genes; Genetic risk; Mutation carriers; Statistics; Tumour pathology; Tumourmorphology

Indexed keywords

EID: 84858309789     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32834e8e5b     Document Type: Article

References (59)

1. Antoniou AC, Pharoah PDP, McMullan G, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002; 86: 76-83. (Pubitemid 34146344)
2. Dunlop MG, Farrington SM, Nicholl I, et al. Population carrier frequency of hMSH2 and hMLH1 mutations. Br J Cancer 2000; 83: 1643-5. (Pubitemid 32001707)
3. Hampel H, de la Chapelle A. The search for unaffected individuals with Lynch syndrome: do the ends justify the means? Cancer Prev Res 2011; 4: 1-5.
4. Levy-Lahad E, Catane R, Eisenberg S, et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997; 60: 1059-67. (Pubitemid 27194090)
5. Van Der Looij M, Szabo C,BesznyakI,et al. Prevalence offounder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J Cancer 2000; 86: 737-40. (Pubitemid 30249888)
6. Nakagawa H, Nuovo GJ, Zervos EE, et al. Age-related hypermethylation of the 50 region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res 2001; 61: 6991-5. (Pubitemid 32946483)
7. Vasen HFA, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastro-enterology 1999; 116: 1453-6. (Pubitemid 29258894)
8. Antoniou A, Pharoah P, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-30. (Pubitemid 36530000)
9. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94: 1365-72. (Pubitemid 35154141)
10. Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001; 68: 410-9. (Pubitemid 32147810)
11. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 91: 1310-1316.
12. Jenkins MA, Baglietto L, Dowty JG, et al. Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. Clin Gastroenterol Hepatol 2006; 4: 489-98.
13. Southey MC, Jenkins MA, Mead L, et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol 2005; 23: 6524-32. (Pubitemid 46190244)
14. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008; 26: 5783-8.
15. Limburg PJ, Harmsen WS, Chen HH, et al. Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer. Clin Gastroenterol Hepatol 2011; 9: 497-502.
16. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118: 829-34. (Pubitemid 30243745)
17. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005; 23: 7491-6. (Pubitemid 46291812)
18. Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison ofbreast conservation and mastectomy. Breast Cancer Res Treat 2010; 121: 389-98.
19. Goodwin PJ, Phillips KA, West DW. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357: 1555; author reply 6. (Pubitemid 47572648)
20. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) poly-merase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-34.
21. Goodwin PJ, Phillips K-A, West DW, et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an international prospective breast cancer family registry population-based cohort study. J Clin Oncol 2011; 29: in press.
22. Phillips K, Milne RL, Rookus MA, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers: A combined analysis from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), the International BRCA1 and BRCA2Carrier Cohort Study (IBCCS), and the Breast Cancer Family Registry (BCFR). ASCO Meeting Abstracts 2011; 29 (15 Suppl): 1500.
23. Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 2011; 60: 950-7.
24. Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011; 103: 863-75.
25. Dite GS, Jenkins MA, Southey MC, et al. Familial risks, early-onset breast cancer, and BRCA1 and BRCA2 germline mutations. J Natl Cancer Inst 2003; 95: 448-57. (Pubitemid 36432419)
26. Antoniou AC, Hardy R, Walker L, et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 2008; 45: 425-31. (Pubitemid 351977132)
27. Pouchet CJ, Wong N, Chong G, et al. A comparison of models used to predict MLH1, MSH2 and MSH6 mutation carriers. Ann Oncol 2009; 20: 681-8.
28. Tresallet C, Brouquet A, Julie C, et al. Evaluation of predictive models for the identification in daily practice of patients with lynch syndrome. Int J Cancer 2011; Apr 25: Epub ahead of print.
29. Imperiale TF, Wagner DR, Lin CY, et al. Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer. Ann Intern Med 2003; 139: 959-65.
30. Kim DJ, Rockhill B, Colditz GA. Validation of the Harvard Cancer Risk Index: a prediction tool for individual cancer risk. J Clin Epidemiol 2004; 57: 332-40. (Pubitemid 38609271)
31. Ma E, Sasazuki S, Iwasaki M, et al. 10-Year risk of colorectal cancer: development and validation of a prediction model in middle-aged Japanese men. Cancer Epidemiol 2010; 34: 534-41.
32. Park Y, Freedman AN, Gail MH, et al. Validation of a colorectal cancer risk prediction model among white patients age 50 years and older. J Clin Oncol 2009; 27: 694-8.
33. Lenz H-J. First Amsterdam, then Bethesda, now Melbourne? J Clin Oncol 2005; 23: 6445-9. (Pubitemid 46190232)
34. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50: 113-30. (Pubitemid 44953403)
35. Jenkins MA, Hayashi S, O'Shea AM, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 2007; 133: 48-56. (Pubitemid 47039240)
36. Loughrey MB, Waring PM, Tan A, et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 2007; 6: 301-10. (Pubitemid 47175009)
37. Mavaddat N, Pharoah P, Blows F, et al. Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. Breast Cancer Res 2010; 12: R10.
38. James PA, Doherty R, Harris M, et al. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol 2006; 24: 707-15. (Pubitemid 46630438)
39. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998; 90: 1138-45. (Pubitemid 28380718)
40. Lakhani SR, Gusterson BA, Jacquemier J, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000; 6: 782-9. (Pubitemid 30159330)
41. Armes JE, Egan AJ, Southey MC, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998; 83: 2335-45. (Pubitemid 28533503)
42. Armes JE, Trute L, White D, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999; 59: 2011-7. (Pubitemid 29186179)
43. Southey MC, Ramus SJ, Dowty JG, et al. Morphological predictors of BRCA1 germline mutations in young women with breast cancer. Br J Cancer 2011; 104: 903-9.
44. Ridolfi RL, Rosen PP, Port A, et al. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977; 40: 1365-85. (Pubitemid 8221704)
45. Bane AL, Beck JC, Bleiweiss I, et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 2007; 31: 121-8. (Pubitemid 46036911)
46. Wong EM, Southey MC, Fox SB, et al. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila) 2011; 4: 23-33.
47. The iSource National Breast Cancer Centre. Clinical Practice Guidelines for the Management of Early Breast Cancer. 2nd ed. Canberra: National Health and Medical Research Council, 2001.
48. Petersen GM, Slack J, Nakamura Y. Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenter-ology 1991; 100: 1658-64.
49. The National Breast Cancer Centre. The National Breast Cancer Centre Annual Report 2003-2004. Sydney: The National Breast Cancer Centre, 2004.
50. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010; 12: 93-104.
51. Royal College of Pathologists of Australasia (RCPA). Published protocols. 2011 (cited Aug 2011). http://www.rcpa.edu.au/Publications/Structured Reporting/CancerProtocols.htm
52. John EM, Hopper JL, Beck JC, et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and transla-tional studies of the genetic epidemiology of breast cancer. Breast Cancer Res 2004; 6: R375-89
53. Newcomb PA, Baron J, Cotterchio M, et al. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 2331-43. (Pubitemid 351196365)
54. Mann GJ, Thorne H, Balleine RL, et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 2006; 8: R12.
55. Brohet RM, Goldgar DE, Easton DF, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 2007; 25: 3831-6. (Pubitemid 47477257)
56. Jenkins MA, Dowty JG, Hopper JL, Southey MC. Molecular screening of all colorectal tumors diagnosed before age 50 years followed by genetic testing efficiently identifies Lynch syndrome cases. Int J Cancer 2009; 124: x-xi.
57. Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006; 296: 1479.
58. Baglietto L, Lindor NM, Dowty JG, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 2010; 102: 193-201.
59. Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008; 135: 419.e1-28.e1